Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. SBUX
10. AXP

Go back to Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval

Ocular Therapeutix™ Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery

December 3, 2018 7:00 AM EST

DEXTENZA® (dexamethasone ophthalmic insert) is the First Intracanalicular Insert Approved by the FDA for Drug Delivery

Ocular Therapeutix to Host Conference Call Today at 8:30 am ET

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery.... More